Clinical evidence

Find relevant case studies.

Select an Activa Product and refine your search by clicking on Condition and/or Publication source.

Know what you're looking for? Use the search facility to find a particular paper...

Conference poster

Title Improvement of treatment of patients with venous leg ulcers by a new pain-reducing wound dressing with HydroBalance Download File
Author Dini, Bertone, Barbanera, Brill, Romanelli - Italy
Publication Poster Presentation, Wounds UK Harrogate, November 2008
Key Points 25 patient Clinical Study comparing Suprasorb X and Suprasorb P (foam dressing) with Suprasorb P (foam) alone. Single-blinded, mono-centric, prospective, controlled, randomised explorative comparison measured the trans--epidermal water loss (TEWL), redness for inflammation, skin hydration, wound size and pain.
Title Successful therapy of critically-colonised or locally-infected wounds with a new hydrobalanced biocellulose-based wound dressing with polyhexanide on outpatients Download File
Author Mosti, Mattaliano, Schmitz, Abel
Publication Poster Presentation, Wounds UK Harrogate, November 2008
Key Points 60 patients (11 with critically colonized or locally infected wounds), antimicrobial action, donation and absorption, use under compression ,ulcer healing, bacterial burden, pain, and periwound skin.
Title A cohort study on the treatment of diabetic foot ulcer patients using a monofilament debrider and a collagen dressing Download File
Author Rieke,nurse practitioner diabetic foot
Publication Poster EWMA 2012
Key Points 25 diabetic patients treated with Debrisoft to debride and SuprasorbC to kick start the healing process.

The Debrisoft monafilament debridement pad for use in acute or chronic wounds

The Debrisoft monafilament debridement pad for use in acute or chronic wounds

Publication
Medical technology guidance

Author
National Institute for Health and Care Excellence (NICE)

Key points
New NICE Guidance recommends the use of Debrisoft as part of the management of acute or chronic wounds in community settings. According to NICE, hundreds of thousands of patients with wounds requiring debridement could benefit from Debrisoft. Using Debrisoft on these patients could save the NHS in the region of £15 million annually.

 

This information is not intended as a substitute for the advice of a health care professional. Consumers should rely on the judgement of a health care professional for specific conditions.
Activa is a Registered Trademark of Activa Healthcare Ltd. Lycra and Tactel Micro are Registered Trademarks of DuPont.
Registered in England No. 3631028 VAT No. 716473038

We'd love to hear any ideas or feedback you have about Activa   Yes      No   Please keep me up to date
Thanks for taking the time to share your thoughts with us

Your feedback has been submitted and you will receive a response very soon.

Enter your details below to receive our monthly e-newsletter featuring latest product news, e-learning resources, and other updates relevant to your work as a healthcare professional.
*All fields are required